Vyome Holdings reports Q2 2026 net loss of $720,000; cash rises to $7.9 million
Vyome Holdings reported its second-quarter 2026 results, showing a net loss of approximately $720,000, or $0.10 per share, and total operating expenses of approximately $874,000. The company's cash and cash equivalents rose to approximately $7.9 million from $5.0 million at December 31, 2025, but the six-month net loss widened to $1,705,204 from $602,732 a year earlier, and six-month revenue fell to $58,546 from $248,535.
Key points
- Q2 2026 net loss attributable to common shareholders: approximately $720,000, or $0.10 per basic and diluted share
- Cash and cash equivalents: approximately $7.9 million at June 30, 2026, up from $5.0 million at December 31, 2025
- Six-month net loss: $1,705,204 in 2026 versus $602,732 in 2025; six-month revenues: $58,546 versus $248,535
- Company received the FDA's written response on its VT-1953 clinical development program during the second quarter
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 25, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.